Revised maximum retail prices for 1,364 anti-cancer medicine formulations came into effect on November 9, 2026, according to the Department of Pharmaceuticals. The government estimates that the reported reductions could save consumers ₹3,540.38 crore a year.
The update follows a National Pharmaceutical Pricing Authority measure capping trade margins on 137 anti-cancer drugs. The department said the action was based on recommendations from an expert committee constituted by the Directorate General of Health Services on October 17, 2026.
What the reported numbers cover
As of November 8, 85 pharmaceutical companies had reported revised MRPs for 1,364 formulations covering 121 drugs. The figures describe the implementation reported by companies at that point. The broader measure concerns 137 drugs, so the number of drugs in those reports should not be confused with the total scope of the decision.
According to the department, 679 brands reported reductions of more than 50 per cent. The largest reported fall in MRP was 96.45 per cent. That maximum is the biggest individual reduction reported; it does not mean every medicine covered by the measure has become cheaper by that percentage.
The ₹3,540.38 crore figure is an estimate of annual savings to consumers. It represents the expected financial effect of the lower prices, rather than savings already accumulated since their introduction.
What buyers can check
The department advised consumers to check the revised MRP printed on the medicine pack. It also identified the Pharma Sahi Daam mobile application and the NPPA website as channels for verifying medicine prices.
The government’s November 9 announcement says chemists and hospital pharmacies cannot charge above the revised MRP. For a buyer checking a bill, the relevant comparison is the applicable revised price for the medicine being supplied, rather than the largest percentage reduction mentioned in the announcement.
Where pricing complaints can be raised
The department directed consumers with overcharging or other medicine-pricing complaints to the Pharma Jan Samadhan portal or the NPPA helpline, 1800-111-255.
The announcement concerns retail pricing and the implementation information submitted by companies. It does not set out a new clinical treatment recommendation. Its immediate significance for patients and families is the revised price ceiling and the official channels available to check prices or raise an overcharging complaint.




